Press

At the 22nd DIA Japan Annual Meeting 2025, which will be held at Tokyo Big Sight on Sunday, October 19th, Monday, October 20th, and Tuesday, October 21st, CEO Ikawa will be speaking at a seminar (Monday, October 20th, S18 Hall 3) and our company will be exhibiting at a booth as detailed below.

Venue: Tokyo Big Sight
Seminar Summary: Day 2 | October 20 (Mon) S18 Hall 3 16:25-17:55
Seminar Title: Virtual Reality and the Metaverse Transforming Medical and Clinical Trial Communication
Seminar Details:
In the fields of medical and clinical trials, the revision of ICH E8(R1) and the October 2024 revision of the Declaration of Helsinki have increased the need to foster a culture that supports open dialogue, and to address community and socially vulnerable groups. This calls for a two-way, or even omnidirectional, approach. To respond sincerely to this situation, we need an approach that goes beyond traditional communication methods (face-to-face, telephone, email, etc.) and combines new methods.
This session aims to introduce examples of how digital transformation technologies such as virtual reality (XR) and virtual spaces (the Metaverse) will impact medical practice. We also discuss the impact they will have on clinical trials, which will lead to the “norm of tomorrow,” and discuss the potential for new clinical trial dialogue, focusing on challenges and solutions for their implementation.
Specifically, Dr. Taketo Asano of Osaka University Hospital will chair the session, and as examples from the medical field, Masafumi Sugimura of Juntendo University will introduce the Metaverse Hospital initiative (aiming for universally accessible digital health through virtual hospitals), and Yudai Asai of NTT ConoQ will introduce remote medical support efforts using mixed reality (MR) technology. Additionally, Hiroyo Matsuyama of Amata Inc. will introduce examples from WG1 “Initiatives on Virtual Monitoring Using VR and AR Tools” and WG3 “Utilizing the Metaverse as a New Touchpoint with Patients,” which are active within the Metaverse Medical Challenge (Me2C), a voluntary group of multi-stakeholders, as examples of precedents aimed at introducing these technologies into clinical trials.
Furthermore, based on these lectures, a panel discussion will be held featuring Dr. Keisuke Suzuki of the National Center for Geriatrics and Gerontology, Mr. Yasuaki Nakaoka of Chugai Clinical Research Center, and Mr. Ikawa, CEO of Buzzreach. Drawing on case studies from the medical field, they will discuss the impact, challenges, and solutions of introducing the latest technologies (XR and the Metaverse) into clinical trials.
This session aims to be a new step forward in efforts to ensure diversity and utilize new communication technologies.

■Outline of the 22nd DIA Japan Annual Meeting 2025Sponsors: Ministry of Health, Labour and Welfare / Pharmaceuticals and Medical Devices Agency / Japan Agency for Medical Research and Development / Japan Pharmaceutical Manufacturers of America / Pharmaceutical Research and Manufacturers of America / European Federation of Pharmaceutical Industries and Associations / Japan PDA Pharmaceutical Society / Medical Excellence JAPANExpected

Sponsors : International Society for Pharmaceutical Engineering (ISPE) / ISPOR Japan SectionEndorsement by MHLW, PMDA, AMED, JPMA, PhRMA, EFPIA, PDA, and MEJEndorsement pending by ISPE and ISPOR [Contact] DIA Japan 03-6214-0574 |  JapanAnnual@DIAglobal.orgClick here for the outline of the 22nd DIA Japan Annual Meeting 2025